Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Aclaris Therapeutics

NASDAQ ACRS
$1.18 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 23 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

83.87M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
44.42M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.58
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
71.07M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
12.38 %

Upcoming events Aclaris Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Aclaris Therapeutics

Stock analysis Aclaris Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-1.09 8.74
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
0.53 25.14
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.55 4.38
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.49 0.50
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-54.40 9.54

Price change Aclaris Therapeutics per year

3.04$ 30.38$
Min Max

Summary analysis Aclaris Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Aclaris Therapeutics

Revenue and net income Aclaris Therapeutics

All parameters

Stock news Aclaris Therapeutics

All news
16 January в 15:25

Aclaris Therapeutics CEO Leaves; Strategic Review Underway

16 January в 15:25

Aclaris Therapeutics CEO Leaves; Strategic Review Underway

10 January в 15:35

Aclaris Therapeutics Shares Down 12% Following Top-Line Results for Atopic Dermatitis Treatment

10 January в 15:30

Aclaris Therapeutics Shares Down 12% Following Top-Line Results for Atopic Dermatitis Treatment

20 December 2023 в 00:10

Aclaris Therapeutics to Reduce Workforce by Nearly Half

20 December 2023 в 00:10

Aclaris Therapeutics to Reduce Workforce by Nearly Half

13 November 2023 в 19:40

Aclaris Therapeutics Shares Plumb New Depths After Lead Asset Scrapped

13 November 2023 в 19:40

Aclaris Therapeutics Shares Plumb New Depths After Lead Asset Scrapped

13 November 2023 в 16:30

Aclaris Therapeutics Shares Plummet Premarket on Zunsemetinib Failure

13 November 2023 в 16:30

Aclaris Therapeutics Shares Plummet Premarket on Zunsemetinib Failure

6 March 2023 в 19:05

Aclaris Therapeutics Shares Slide to Two-Year Lows on Study Failure >ACRS

6 March 2023 в 19:00

Aclaris Therapeutics Shares Slide to Two-Year Lows on Study Failure >ACRS

6 March 2023 в 15:45

Aclaris Therapeutics Says Zunsemetinib Study Failed to Meet Efficacy Endpoints

6 March 2023 в 15:45

Aclaris Therapeutics Says Zunsemetinib Study Failed to Meet Efficacy Endpoints

23 November 2022 в 00:25

Aclaris Therapeutics Names New CEO, CFO in Leadership Shuffle

23 November 2022 в 00:25

Aclaris Therapeutics Names New CEO, CFO in Leadership Shuffle

About company Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Address:
640 Lee Road, Wayne, PA, United States, 19087
Company name: Aclaris Therapeutics
Issuer ticker: ACRS
ISIN: US00461U1051
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2015-10-07
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.aclaristx.com

On which stock exchange are Aclaris Therapeutics (ACRS) stocks traded?

Aclaris Therapeutics (ACRS) stocks are traded on NASDAQ.

What is the ticker of Aclaris Therapeutics stocks (ACRS)?

The stock ticker of Aclaris Therapeutics’s stocks or in other words, the code is ACRS. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Aclaris Therapeutics (ACRS) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Aclaris Therapeutics (ACRS) belongs to the «Healthcare» sector and the «Pharmaceuticals» industry.

In what currency are Aclaris Therapeutics (ACRS) stocks traded?

Aclaris Therapeutics (ACRS) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Aclaris Therapeutics (ACRS) stocks today?

The current price of Aclaris Therapeutics stocks on 17.05.2024 is 1.18 dollars. per share.

What is the dynamics of Aclaris Therapeutics (ACRS) stocks from the beginning of the year?

Aclaris Therapeutics (ACRS) quotes have increased by 12.38% from the beginning of the year up to 1.18 dollars. per 1 stocks.

How much did Aclaris Therapeutics (ACRS) stocks increase in мае 2024?

This month Aclaris Therapeutics (ACRS) quotes have increased by -6.35% to 1.18 dollars. per share.

How much are Aclaris Therapeutics (ACRS) stocks worth?

Today, on October, 17.05.2024 Aclaris Therapeutics’s (ACRS) stocks cost 1.18 dollars..

What is the market capitalization of Aclaris Therapeutics (ACRS)?

Capitalization is the market value of Aclaris Therapeutics (ACRS) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 17.05.2024, the market capitalization of Aclaris Therapeutics (ACRS) is estimated at about 83868332 dollars.